Monday , October 23 2017
Home / Letter From The Editor / Editor’s Note, SGLT2-Inhibitor Special Issue #6

Editor’s Note, SGLT2-Inhibitor Special Issue #6

Over the past few months we have brought you the latest information on SGLT2 Inhibitors, examining this new class of drugs from every angle including how they work, prescription insurance coverage, and both clinician and patient experience with this new medication. Jansen, the manufacturer of the only approved SGLT2 Inhibitor, Invokana (canaglifozin), has also ramped up their sales force and is providing webinars and programs to explain this new class to prescribers.

During our discussions with many prescribers we found that there was some hesitation in using this new class of dugs because of the mechanism of action and that using it might be "cheating" to fix blood sugars, so we have prepared an article for you looking at this idea.